PLATELET AGGREGATION IN THE END-STAGE RENAL DISEASE – DIFFERENCES BETWEEN PATIENTS TREATED WITH HEMODIALYSIS AND PERITONEAL DIALYSIS (CROSBI ID 322269)
Prilog u časopisu | izvorni znanstveni rad
Podaci o odgovornosti
Martinović, Željka ; Bašić-Jukić Nikolina ; Katalinić, Lea ; Bandić Pavlović, Daniela ; Hudolin, Tvrtko ; Kes, Petar
engleski
PLATELET AGGREGATION IN THE END-STAGE RENAL DISEASE – DIFFERENCES BETWEEN PATIENTS TREATED WITH HEMODIALYSIS AND PERITONEAL DIALYSIS
End-stage renal disease patients (ESRD) suffer from procoagulant abnormalities that lead to excessive cardiovascular events, as well as from platelet dysfunction manifesting as an increased risk of bleeding. The exact pathogenesis of complex hemostatic disorders in ESRD patients is not completely understood. The aim of our study was to investigate the possible different effects of hemodialysis (HD) and peritoneal dialysis (PD) on platelet function in patients with ESRD by using the platelet function analyzer (PFA-100) which in vitro simulates the process of aggregation and platelet activation. Tests were performed with collagen/epinephrine (COL/EPI) and collagen/adenosine-5-diphosphate (COL/ADP) cartridges. The study included 44 patients with ESRD undergoing regular HD (n=32) or PD (n=12). Although there were no significant differences in COL/EPI and COL/ADP tests, it is indicative that more than 50% of HD patients had COL/EPI test values above the upper limit. These findings correlated with a higher chance for bleeding in HD group. Additionally, patients in HD group were significantly older and had significantly lower platelet count compared to PD patients.
platelet function, end-stage renal disease, hemodialysis, peritoneal dialysis
nije evidentirano
nije evidentirano
nije evidentirano
nije evidentirano
nije evidentirano
nije evidentirano